Zacks Investment Research

Coronavirus crisis has dealt a blow to the broader investing world, pushing Wall Street into a bear market territory. But one zone that performed worse even during the rosier times, seems to be...

With the coronavirus pandemic wrecking the airline industry, federal help was sought by U.S. airlines to stay afloat. Carriers received positive news on that front over the past five trading days with...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth...

While most of the sectors, economies and companies are suffering due to the coronavirus pandemic, telehealth service provider Teladoc Health, Inc. (NYSE:TDOC) continues to witness growth.In the...

Friday, March 27, 2020The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL),...

Northern Technologies (NTIC) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended February 2020. This widely-known consensus...

Wall Street expects a year-over-year decline in earnings on higher revenues when Constellation Brands (STZ) reports results for the quarter ended February 2020. While this widely-known consensus...

AeroVironment (AVAV) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with...

Investors might want to bet on Canadian Solar (CSIQ), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of...

Investors might want to bet on Charter Communications (NASDAQ:CHTR), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates,...

Audioeye, Inc. (AEYE) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock...

AcelRx Pharmaceuticals (ACRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their...